Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

MULTI-C Multiomic DNA Chip Technology for Blood Cancer Profiling

Coordinator
Tel Aviv University, Israel
Runs
1 October 2025 to 31 March 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101248654

What the project is doing

In the project's own words, from its summary on CORDIS.

Blood cancers remain challenging to diagnose and monitor due to the standard of care requirement for bone marrow biopsies and limitations in current biomarker detection technologies. DNA modifications, specifically 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)—are powerful epigenetic regulators in blood cancer development, providing valuable diagnostic and prognostic information. Despite their clinical importance, current technologies fail to simultaneously detect both 5mC and 5hmC with precision and efficiency, creating a significant barrier to clinical implementation of these epigenetic marks.

This proposal introduces an innovative microarray platform that overcomes these limitations by enabling simultaneous profiling of both 5mC and 5hmC modifications from blood samples within a single, cost-effective assay. Unlike current methods that struggle with modification differentiation, sample degradation, and complex workflows, our technology offers a streamlined approach that preserves sample integrity while delivering superior diagnostic accuracy.

Our innovation lies in the ability to distinguish different cytosine modifications (MULTI-C), which provides significantly enhanced diagnostic accuracy compared to single-marker approaches. The platform's remarkable sensitivity allows detection from minimal DNA inputs, making it ideally suited for minimally-invasive liquid biopsy applications—a critical advancement for patient monitoring and precision medicine in hematological malignancies.

This research has the potential to transform how blood cancers are diagnosed, monitored, and treated by addressing a fundamental technological gap in epigenetic profiling and reducing the need for bone marrow biopsies.

Topics

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI